 4D pharma PLC AIM:DDD, NASDAQ:LBPS has shared highly encouraging follow-up data from its early-stage asthma trial using its lead live biotherapeutic asset. The first part of the phase III study revealed multiple signs that MRx-4DP0004 might help control the condition, supporting its move onto the second stage of the clinical evaluation process. 